Analysis uncovers scar-like transcriptomic profile in bladder cancer, indicating improved clinical outcomes post-neoadjuvant therapy.
Figure S4. Twelve of the thirteen 13 scar-like cases previously identified in pembrolizumab-treated tumors (panel A) classified as stroma-rich by the consensus subtyping model, representing a subgroup with improved clinical outcomes (panel B)
No takes yet. Share an insight, caveat, or question.
Jong et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: